Grifols (WBO:GRF) Operating Margin %: 14.65% (As of Mar. 2026) — 16% Below Median


WBO:GRF Grifols SA WBO:GRF
83 GF Score
Price €9.04
GF Value €11.06
! 6 Warning Signs
View Full Analysis

What is Grifols Operating Margin %?

Grifols WBO:GRF -0.09% 83 Operating Margin % is 14.65% as of Mar. 2026, which is 16% below its 10-year median of 17.45. GuruFocus rates WBO:GRF with a GF Score™ of 83/100 and a GF Value™ of €11.06. The stock has 6 warning signs investors should review. Among 955 Drug Manufacturers companies, Grifols ranks better than 74.55% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Grifols's Operating Income for the three months ended in Mar. 2026 was €249 Mil. Grifols's Revenue for the three months ended in Mar. 2026 was €1,700 Mil. Therefore, Grifols's Operating Margin % for the quarter that ended in Mar. 2026 was 14.65%.

Good Sign:

Grifols SA operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Grifols's Operating Margin % or its related term are showing as below:

WBO:GRF' s Operating Margin % Range Over the Past 10 Years
Min: 10.89   Med: 17.45   Max: 23.24
Current: 16.48


WBO:GRF's Operating Margin % is ranked better than
74.55% of 955 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs WBO:GRF: 16.48

Grifols's 5-Year Average Operating Margin % Growth Rate was 1.50% per year.

Grifols's Operating Income for the three months ended in Mar. 2026 was €249 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €1,226 Mil.


Grifols  (WBO:GRF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Grifols Operating Margin % Related Terms


Grifols Operating Margin % Historical Data

* Premium members only.

The historical data trend for Grifols's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grifols Operating Margin % Chart

Grifols Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.40 11.20 10.89 16.01 16.63

Grifols Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.34 18.48 18.88 13.90 14.65

WBO:GRF vs LLY, JNJ, ABBV: Operating Margin % Comparison

For the Drug Manufacturers - General subindustry, Grifols's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Grifols Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Grifols's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Grifols's Operating Margin % falls into.


WBO:GRF
83GF Score
Grifols SA WBO:GRF
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grifols Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Grifols's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=1251 / 7524
=16.63 %

Grifols's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=249 / 1700
=14.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of 14.65% mean?
Grifols (WBO:GRF) has a Operating Margin % of 14.65% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Grifols and its competitors. This is 16% below median its historical median of 17.45. Over the past decade, Grifols' Operating Margin % has ranged from 10.89 to 23.24. According to the industry distribution chart, Grifols ranks #243 out of 955 companies in the Drug Manufacturers industry, placing it in the top 25.4%.
Is Grifols' Operating Margin % too high?
Grifols' current Operating Margin % of 14.65% is 16% below median its 10-year median of 17.45. Over the past 10 years, this metric has ranged from a low of 10.89 to a high of 23.24. The Drug Manufacturers industry median Operating Margin % is 7.45. Grifols' value of 14.65% is 96.6% above this industry median. Based on the distribution chart, Grifols ranks #243 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Grifols has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Grifols' Operating Margin % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Grifols ranks #243 out of 955 companies for Operating Margin %. This puts Grifols in the upper half of its industry. The industry median Operating Margin % is 7.45. Grifols' value of 14.65% is 96.6% above this benchmark. Historically, Grifols' own Operating Margin % has ranged from 10.89 to 23.24 over the past decade. While the company's 10-year median is 17.45 vs. the industry median of 7.45, Grifols has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Grifols's current Operating Margin % of 14.65% is 96.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Grifols and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Grifols's current Operating Margin % is 14.65%, which is 16% below median its own 10-year median of 17.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grifols stock overvalued right now?
Grifols (WBO:GRF) has a current Operating Margin % of 14.65%. The stock's GF Value™ is €11.06, compared to a current price of €9.04 — trading 18.3% below its estimated fair value. The current Operating Margin % is 14.65%, which is 16% below median its 10-year median of 17.45 and 96.6% above the Drug Manufacturers industry median of 7.45. Grifols' overall GF Score™ is 83/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Grifols (WBO:GRF), the current Operating Margin % is 14.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grifols (WBO:GRF) Overvalued in 2026?

Based on GuruFocus' analysis, Grifols stock appears to be undervalued. The current stock price of €9.04 is trading 18.3% below its estimated GF Value™ of €11.06.

Key valuation signals for WBO:GRF:

  • Operating Margin %: 14.65% (16% below median its 10-year median of 17.45)
  • GF Value™: €11.06 vs. price of €9.04 (18.3% below fair value)
  • GF Score™: 83/100 with 6 warning signs
  • Industry Position: 96.6% above the Drug Manufacturers median (#243 of 955)

No single metric tells the full story. See the WBO:GRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Grifols Business Description

Address Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
Grifols SA is a healthcare company engaged in activities related to plasma-derived products and diagnostic solutions. The group has four reportable segments: Biopharma, Diagnostic, Bio Supplies, and Others. The Biopharma segment focuses on products derived from human plasma for therapeutic use, while the Diagnostic segment includes the marketing of diagnostic testing equipment and reagents. The Bio Supplies segment covers biological products for non-therapeutic use and plasma sales to third parties, and the Others segment includes manufacturing services, research activities, and complementary pharmaceutical products.
83GF Score

Get the complete analysis for WBO:GRF

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.04
Price
€11.06
GF Value